{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:41:47Z","timestamp":1785339707744,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["R01CE003347"],"award-info":[{"award-number":["R01CE003347"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG060975"],"award-info":[{"award-number":["R01AG060975"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA048001"],"award-info":[{"award-number":["R01DA048001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG064589"],"award-info":[{"award-number":["R01AG064589"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG025152"],"award-info":[{"award-number":["R01AG025152"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug interactions involving benzodiazepines and related drugs (BZDs) are increasingly recognized as a contributor to increased risk of unintentional traumatic injury. Yet, it remains unknown to what extent drug interaction triads (3DIs) may amplify BZDs\u2019 inherent injury risk. We identified BZD 3DI signals associated with increased injury rates by conducting high-throughput pharmacoepidemiologic screening of 2000\u20132019 Optum\u2019s health insurance data. Using self-controlled case series design, we included patients aged\u2009\u2265\u200916\u00a0years with an injury while using a BZD\u2009+\u2009co-dispensed medication (i.e., base pair). During base pair-exposed observation time, we identified other co-dispensed medications as candidate interacting precipitants. Within each patient, we compared injury rates during time exposed to the drug triad versus to the base pair only using conditional Poisson regression, adjusting for time-varying covariates. We calculated rate ratios (RRs) with 95% confidence intervals (CIs) and accounted for multiple estimation via semi-Bayes shrinkage. Among the 65,123 BZD triads examined, 79 (0.1%) were associated with increased injury rates and considered 3DI signals. Adjusted RRs for signals ranged from 3.01 (95% CI =\u00a01.53\u20135.94) for clonazepam\u2009+\u2009atorvastatin with cefuroxime to 1.42 (95% CI\u2009=\u20091.00\u20132.02, p\u2009=\u20090.049) for alprazolam\u2009+\u2009hydrocodone with tizanidine. These signals may help researchers prioritize future etiologic studies to investigate higher-order BZD interactions.<\/jats:p>","DOI":"10.1038\/s41598-022-19551-4","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T12:05:20Z","timestamp":1663329920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population-based screening to detect benzodiazepine drug-drug-drug interaction signals associated with unintentional traumatic injury"],"prefix":"10.1038","volume":"12","author":[{"given":"Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Brensinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Acton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren B.","family":"Bilker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadeer K.","family":"Dawwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Miano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Phuong","family":"Pham Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"19551_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.amepre.2016.02.014","volume":"51","author":"CS Hwang","year":"2016","unstructured":"Hwang, C. S. et al. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002\u20132014. Am. J. Prev. Med. 51, 151\u2013160 (2016).","journal-title":"Am. J. Prev. Med."},{"key":"19551_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/pds.3951","volume":"25","author":"CN Kaufmann","year":"2016","unstructured":"Kaufmann, C. N., Spira, A. P., Alexander, G. C., Rutkow, L. & Mojtabai, R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993\u20132010. Pharmacoepidemiol. Drug Saf. 25, 637\u2013645 (2016).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"19551_CR3","doi-asserted-by":"publisher","first-page":"e187399","DOI":"10.1001\/jamanetworkopen.2018.7399","volume":"2","author":"SD Agarwal","year":"2019","unstructured":"Agarwal, S. D. & Landon, B. E. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Netw. Open 2, e187399\u2013e187399 (2019).","journal-title":"JAMA Netw. Open"},{"key":"19551_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","volume":"70","author":"DT Maust","year":"2019","unstructured":"Maust, D. T., Lin, L. A. & Blow, F. C. Benzodiazepine use and misuse among adults in the United States. Psychiatr. Serv. 70, 97\u2013106 (2019).","journal-title":"Psychiatr. Serv."},{"key":"19551_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1176\/appi.ps.201700095","volume":"69","author":"CN Kaufmann","year":"2018","unstructured":"Kaufmann, C. N., Spira, A. P., Depp, C. A. & Mojtabai, R. Long-term use of benzodiazepines and nonbenzodiazepine hypnotics, 1999\u20132014. Psychiatr. Serv. 69, 235\u2013238 (2018).","journal-title":"Psychiatr. Serv."},{"key":"19551_CR6","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1001\/jama.1989.03430230088031","volume":"262","author":"WA Ray","year":"1989","unstructured":"Ray, W. A., Griffin, M. R. & Downey, W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 262, 3303\u20133307 (1989).","journal-title":"JAMA"},{"key":"19551_CR7","doi-asserted-by":"publisher","first-page":"e202051","DOI":"10.1001\/jamanetworkopen.2020.2051","volume":"3","author":"DT Maust","year":"2020","unstructured":"Maust, D. T. et al. Association of Medicare Part D benzodiazepine coverage expansion with changes in fall-related injuries and overdoses among Medicare advantage beneficiaries. JAMA Netw. Open 3, e202051\u2013e202051 (2020).","journal-title":"JAMA Netw. Open"},{"key":"19551_CR8","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/archinte.164.14.1567","volume":"164","author":"AK Wagner","year":"2004","unstructured":"Wagner, A. K. et al. Benzodiazepine use and hip fractures in the elderly: Who is at greatest risk?. Arch. Intern. Med. 164, 1567\u20131572 (2004).","journal-title":"Arch. Intern. Med."},{"key":"19551_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/pds.2031","volume":"19","author":"K Zint","year":"2010","unstructured":"Zint, K. et al. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol. Drug Saf. 19, 1248\u20131255 (2010).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"19551_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174730","volume":"12","author":"K Donnelly","year":"2017","unstructured":"Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A. & Carter, B. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLoS ONE 12, e0174730 (2017).","journal-title":"PLoS ONE"},{"key":"19551_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(98)04087-2","volume":"352","author":"F Barbone","year":"1998","unstructured":"Barbone, F. et al. Association of road-traffic accidents with benzodiazepine use. Lancet 352, 1331\u20131336 (1998).","journal-title":"Lancet"},{"key":"19551_CR12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2165\/11533170-000000000-00000","volume":"24","author":"BE Smink","year":"2010","unstructured":"Smink, B. E., Egberts, A. C., Lusthof, K. J., Uges, D. R. & De Gier, J. J. The relationship between benzodiazepine use and traffic accidents. CNS Drugs 24, 639\u2013653 (2010).","journal-title":"CNS Drugs"},{"key":"19551_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/clpt.2011.3","volume":"89","author":"L Orriols","year":"2011","unstructured":"Orriols, L. et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin. Pharmacol. Ther. 89, 595\u2013601 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"19551_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40268-017-0207-7","volume":"17","author":"J Brandt","year":"2017","unstructured":"Brandt, J. & Leong, C. Benzodiazepines and Z-drugs: An updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D 17, 493\u2013507 (2017).","journal-title":"Drugs R D"},{"key":"19551_CR15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.5665\/sleep.5742","volume":"39","author":"SE Tom","year":"2016","unstructured":"Tom, S. E., Wickwire, E. M., Park, Y. & Albrecht, J. S. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep 39, 1009\u20131014 (2016).","journal-title":"Sleep"},{"key":"19551_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/089198870001300309","volume":"13","author":"MD Llorente","year":"2000","unstructured":"Llorente, M. D., David, D., Golden, A. G. & Silverman, M. A. Defining patterns of benzodiazepine use in older adults. J. Geriatr. Psychiatry Neurol. 13, 150\u2013160 (2000).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"19551_CR17","first-page":"5","volume":"358","author":"E Patorno","year":"2017","unstructured":"Patorno, E., Glynn, R. J., Levin, R., Lee, M. P. & Huybrechts, K. F. Benzodiazepines and risk of all cause mortality in adults: Cohort study. BMJ 358, 5 (2017).","journal-title":"BMJ"},{"key":"19551_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2165\/00002018-200528120-00008","volume":"28","author":"DD French","year":"2005","unstructured":"French, D. D. et al. Effect of concomitant use of benzodiazepines and other drugs on the risk of injury in a veterans population. Drug Saf. 28, 1141\u20131150 (2005).","journal-title":"Drug Saf."},{"key":"19551_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/injuryprev-2015-041616","volume":"22","author":"JA Haagsma","year":"2016","unstructured":"Haagsma, J. A. et al. The global burden of injury: Incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. Inj. Prev. 22, 3\u201318 (2016).","journal-title":"Inj. Prev."},{"key":"19551_CR20","unstructured":"United States Senate Special Committee on Aging. Falls Prevention: National, State, and Local Solutions to Better Support Seniors. https:\/\/www.aging.senate.gov\/imo\/media\/doc\/SCA_Falls_Report_2019.pdf (2019)."},{"key":"19551_CR21","unstructured":"U.S. Department of Transportation National Highway Traffic Safety Administration. Multiple Medications and Vehicle Crashes: Analysis of Databases. https:\/\/trid.trb.org\/view\/863878 (2008)."},{"key":"19551_CR22","unstructured":"Horn, J. R. Triple Drug Interactions. https:\/\/www.pharmacytimes.com\/view\/interactions-0111 (2011)."},{"key":"19551_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/0018578719894702","volume":"55","author":"JH Watanabe","year":"2020","unstructured":"Watanabe, J. H. & Yang, J. Hospitalization and combined use of opioids, benzodiazepines, and muscle relaxants in the United States. Hosp. Pharm. 55, 286\u2013291 (2020).","journal-title":"Hosp. Pharm."},{"key":"19551_CR24","first-page":"427","volume":"39","author":"C Witenko","year":"2014","unstructured":"Witenko, C. et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P T. 39, 427 (2014).","journal-title":"P T."},{"key":"19551_CR25","first-page":"5","volume":"354","author":"I Petersen","year":"2016","unstructured":"Petersen, I., Douglas, I. & Whitaker, H. Self controlled case series methods: An alternative to standard epidemiological study designs. BMJ 354, 5 (2016).","journal-title":"BMJ"},{"key":"19551_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110531","volume":"130","author":"CE Leonard","year":"2020","unstructured":"Leonard, C. E. et al. Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. Biomed. Pharmacother. 130, 110531 (2020).","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"19551_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/cpt.2195","volume":"110","author":"CE Leonard","year":"2021","unstructured":"Leonard, C. E. et al. Population-based signals of antidepressant drug interactions associated with unintentional traumatic injury. Clin. Pharmacol. Ther. 110(2), 409\u2013423 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"19551_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.1146","volume":"105","author":"YH Nam","year":"2019","unstructured":"Nam, Y. H. et al. Serious hypoglycemia and use of warfarin in combination with sulfonylureas or metformin. Clin. Pharmacol. Ther. 105, 210\u2013218 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"19551_CR29","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/cpt.1885","volume":"108","author":"YH Nam","year":"2020","unstructured":"Nam, Y. H. et al. Sulfonylureas and metformin were not associated with an increased rate of serious bleeding in warfarin users: A self-controlled case series study. Clin. Pharmacol. Ther. 108, 1010\u20131017 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"19551_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/cpt.2377","volume":"111","author":"NY Hee","year":"2022","unstructured":"Hee, N. Y. et al. Angiotensin-converting enzyme inhibitors used concomitantly with insulin secretagogues and the risk of serious hypoglycemia. Clin. Pharmacol. Ther. 111(1), 218\u2013226 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"19551_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/EDE.0000000000000638","volume":"28","author":"X Han","year":"2017","unstructured":"Han, X. et al. Biomedical informatics approaches to identifying drug-drug interactions: Application to insulin secretagogues. Epidemiology 28(3), 459\u2013468 (2017).","journal-title":"Epidemiology"},{"key":"19551_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cpt.1845","volume":"108","author":"M Zhou","year":"2020","unstructured":"Zhou, M. et al. Pharmacoepidemiologic screening of potential oral anticoagulant drug interactions leading to thromboembolic events. Clin. Pharmacol. Ther. 108, 377\u2013386 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"19551_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-18318-6","volume":"7","author":"CE Leonard","year":"2017","unstructured":"Leonard, C. E. et al. Thromboembolic and neurologic sequelae of discontinuation of an antihyperlipidemic drug during ongoing warfarin therapy. Sci. Rep. 7, 1\u201310 (2017).","journal-title":"Sci. Rep."},{"key":"19551_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111559","volume":"139","author":"TPP Nguyen","year":"2021","unstructured":"Nguyen, T. P. P., Brensinger, C. M., Bilker, W. B., Hennessy, S. & Leonard, C. E. Evaluation of serious bleeding signals during concomitant use of clopidogrel and hypnotic drugs. Biomed. Pharmacother. 139, 111559 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"19551_CR35","unstructured":"American College of Surgeons. National Trauma Data Standard: Data Dictionary. https:\/\/www.facs.org\/quality-programs\/trauma\/tqp\/center-programs\/ntdb\/ntds\/archiveddictionary (2015)"},{"key":"19551_CR36","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s10926-015-9582-5","volume":"25","author":"JM Sears","year":"2015","unstructured":"Sears, J. M., Bowman, S. M., Rotert, M. & Hogg-Johnson, S. A new method to classify injury severity by diagnosis: Validation using workers\u2019 compensation and trauma registry data. J. Occup. Rehabil. 25, 742\u2013751 (2015).","journal-title":"J. Occup. Rehabil."},{"key":"19551_CR37","unstructured":"Centers for Disease Control and Prevention. Recommended framework for presenting injury mortality data. MMWR: Recommendations and reports: Morbidity and mortality weekly report. In Recommendations and reports\/Centers for Disease Control, vol. 46, 1\u201330 (1997)."},{"key":"19551_CR38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/bimj.201800019","volume":"60","author":"HJ Whitaker","year":"2018","unstructured":"Whitaker, H. J., Steer, C. D. & Farrington, C. P. Self-controlled case series studies: Just how rare does a rare non-recurrent outcome need to be?. Biom. J. 60, 1110\u20131120 (2018).","journal-title":"Biom. J."},{"key":"19551_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/sim.4780110208","volume":"11","author":"S Greenland","year":"1992","unstructured":"Greenland, S. A semi-Bayes approach to the analysis of correlated multiple associations, with an application to an occupational cancer-mortality study. Stat. Med. 11, 219\u2013230 (1992).","journal-title":"Stat. Med."},{"key":"19551_CR40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10654-009-9393-0","volume":"24","author":"U Str\u00f6mberg","year":"2009","unstructured":"Str\u00f6mberg, U. Empirical Bayes and semi-Bayes adjustments for a vast number of estimations. Eur. J. Epidemiol. 24, 737\u2013741 (2009).","journal-title":"Eur. J. Epidemiol."},{"key":"19551_CR41","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1089\/pop.2019.0128","volume":"23","author":"S Musich","year":"2020","unstructured":"Musich, S., Wang, S. S., Slindee, L. B., Ruiz, J. & Yeh, C. S. Concurrent use of opioids with other central nervous system-active medications among older adults. Popul. Health Manag. 23, 286\u2013296 (2020).","journal-title":"Popul. Health Manag."},{"key":"19551_CR42","first-page":"847","volume":"57","author":"N He","year":"2002","unstructured":"He, N., Zhang, W.-Q., Shockley, D. & Edeki, T. Inhibitory effects of H1-antihistamines on CYP2D6-and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur. J. Epidemiol. 57, 847\u2013851 (2002).","journal-title":"Eur. J. Epidemiol."},{"key":"19551_CR43","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/00004714-199806000-00015","volume":"18","author":"K Venkatakrishnan","year":"1998","unstructured":"Venkatakrishnan, K., Greenblatt, D. J., von Moltke, L. L. & Shader, R. I. Alprazolam is another substrate for human cytochrome P450\u20133A isoforms. J. Clin. Psychopharmacol. 18, 256 (1998).","journal-title":"J. Clin. Psychopharmacol."},{"key":"19551_CR44","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/009127009903901102","volume":"39","author":"R Yuan","year":"1999","unstructured":"Yuan, R., Flockhart, D. A. & Balian, J. D. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J. Clin. Pharmacol. 39, 1109\u20131125 (1999).","journal-title":"J. Clin. Pharmacol."},{"key":"19551_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2125.2011.04007.x","volume":"72","author":"B Malhotra","year":"2011","unstructured":"Malhotra, B. et al. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br. J. Clin. Pharmacol. 72, 263\u2013269 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"19551_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan, E. T. Impact of infectious and inflammatory disease on cytochrome P450\u2013mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther. 85, 434\u2013438 (2009).","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19551-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19551-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T08:14:44Z","timestamp":1668845684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19551-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19551"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19551-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"23 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Leonard is an Executive Committee Member of and Dr. Hennessy directs the University of Pennsylvania\u2019s Center for Real-World Effectiveness and Safety of Therapeutics. The Center receives funds from Pfizer and Sanofi to support pharmacoepidemiology education. Dr. Leonard recently received honoraria from the American College of Clinical Pharmacy Foundation, HealthCanada, the University of Florida, the University of Massachusetts, the Scientific and Data Coordinating Center for the NIDDK-funded Chronic Renal Insufficiency Cohort Study, and the Consortium for Medical Marijuana Clinical Outcomes Research. Dr. Leonard is a Special Government Employee of the United States (US) Food and Drug Administration and consults for their Reagan-Udall Foundation. Dr. Leonard receives travel support from John Wiley & Sons. Dr. Leonard\u2019s spouse is an employee of Merck; neither Dr. Leonard nor his spouse owns stock in the company. Dr. Horn is co-author and publisher of <i>The Top 100 Drug Interactions: A Guide to Patient Management<\/i> and a consultant to Urovant Sciences and Seegnal US. Dr. Bilker serves on multiple data safety monitoring boards for Genentech. Dr. Hennessy has consulted for multiple pharmaceutical companies. Dr. Pham Nguyen receives support from Acadia Pharmaceuticals Inc., unrelated to this project. All other authors declared no competing interests for this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15569"}}